The company previously manufactured plastic thermoware products but has ceased all industrial operations and sold its primary manufacturing assets. It currently generates minimal income from interest and miscellaneous write-backs while evaluating potential liquidation or new business avenues.
The company has no competitive advantage as it has exited its core manufacturing business and sold its plant and machinery. Financial metrics show zero revenue from operations and massive net margins that are only positive in years with one-time debt write-backs.
Capital allocation has been focused on survival and debt settlement rather than growth. The company sold its core land and buildings to settle liabilities and currently relies on unsecured loans from directors to fund minimal administrative overhead.
The company's attempt at a corporate insolvency resolution process failed to attract a viable suitor, leading to a court-ordered liquidation of remaining scrap assets. The unsecured loans from directors, which were the only thing keeping the lights on for the two remaining employees, were withdrawn or subordinated during the legal proceedings. As the listing of promoter shares diluted the remaining equity, the 'margin of safety' proved to be a mirage because the underlying business had already ceased to exist, leaving shareholders with nothing but a shell company that was eventually delisted.
RichFakir rates MPL Plastics Ltd's business quality as poor — 16/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, MPL Plastics Ltd is trading about 83% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on MPL Plastics Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of MPL Plastics Ltd's fair value is about ₹39 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →